Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stuart Roger Lipsitz, Sc.D.

Co-Author

This page shows the publications co-authored by Stuart Lipsitz and Toni Choueiri.
Connection Strength

2.388
  1. Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. Cancer Cell. 2021 08 09; 39(8):1042-1044.
    View in: PubMed
    Score: 0.247
  2. Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology. 2011 Jul; 78(1):93-8.
    View in: PubMed
    Score: 0.122
  3. Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. JAMA Oncol. 2021 03 01; 7(3):458-460.
    View in: PubMed
    Score: 0.060
  4. Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Netw Open. 2020 03 02; 3(3):e201839.
    View in: PubMed
    Score: 0.056
  5. Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):410-418.
    View in: PubMed
    Score: 0.055
  6. Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. J Immunother Cancer. 2019 11 07; 7(1):289.
    View in: PubMed
    Score: 0.055
  7. Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. J Natl Compr Canc Netw. 2019 09 01; 17(9):1049-1058.
    View in: PubMed
    Score: 0.054
  8. Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis. 2020 03; 23(1):81-87.
    View in: PubMed
    Score: 0.054
  9. Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clin Genitourin Cancer. 2019 10; 17(5):e1060-e1068.
    View in: PubMed
    Score: 0.054
  10. Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. J Urol. 2019 04; 201(4):728-734.
    View in: PubMed
    Score: 0.053
  11. Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 04; 201(4):735-741.
    View in: PubMed
    Score: 0.053
  12. Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz003.
    View in: PubMed
    Score: 0.052
  13. Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329.
    View in: PubMed
    Score: 0.052
  14. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Ann Surg Oncol. 2019 Jan; 26(1):297-305.
    View in: PubMed
    Score: 0.051
  15. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol. 2019 04; 75(4):552-555.
    View in: PubMed
    Score: 0.051
  16. Use of Preventive Health Services Among Cancer Survivors in the U.S. Am J Prev Med. 2018 12; 55(6):830-838.
    View in: PubMed
    Score: 0.051
  17. Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. Urol Oncol. 2018 09; 36(9):400.e15-400.e22.
    View in: PubMed
    Score: 0.051
  18. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019 03; 22(1):125-136.
    View in: PubMed
    Score: 0.051
  19. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Eur Urol Oncol. 2018 05; 1(1):83-90.
    View in: PubMed
    Score: 0.050
  20. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018 09; 200(3):573-581.
    View in: PubMed
    Score: 0.049
  21. The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urol Oncol. 2018 05; 36(5):238.e7-238.e17.
    View in: PubMed
    Score: 0.049
  22. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229.
    View in: PubMed
    Score: 0.049
  23. Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urol Oncol. 2018 03; 36(3):88.e1-88.e9.
    View in: PubMed
    Score: 0.048
  24. Variation in the use of active surveillance for low-risk prostate cancer. Cancer. 2018 Jan 01; 124(1):55-64.
    View in: PubMed
    Score: 0.047
  25. Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clin Genitourin Cancer. 2017 Aug 24.
    View in: PubMed
    Score: 0.047
  26. Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. Eur Urol. 2018 Mar; 73(3):445-451.
    View in: PubMed
    Score: 0.047
  27. The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICAREĀ® Military Database. J Urol. 2017 12; 198(6):1295-1300.
    View in: PubMed
    Score: 0.047
  28. Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. J Urol. 2017 11; 198(5):1061-1068.
    View in: PubMed
    Score: 0.046
  29. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487.
    View in: PubMed
    Score: 0.046
  30. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol. 2017 Mar 10; 35(8):852-860.
    View in: PubMed
    Score: 0.045
  31. Prog Urol. 2016 Nov; 26(13):676-677.
    View in: PubMed
    Score: 0.045
  32. Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536.
    View in: PubMed
    Score: 0.044
  33. Determinants of cancer screening in Asian-Americans. Cancer Causes Control. 2016 08; 27(8):989-98.
    View in: PubMed
    Score: 0.044
  34. The influence of marital status on the use of breast, cervical, and colorectal cancer screening. Prev Med. 2016 08; 89:140-145.
    View in: PubMed
    Score: 0.043
  35. Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. J Urol. 2016 Oct; 196(4):1090-5.
    View in: PubMed
    Score: 0.043
  36. Data on Medicare eligibility and cancer screening utilization. Data Brief. 2016 Jun; 7:679-81.
    View in: PubMed
    Score: 0.043
  37. The impact of Medicare eligibility on cancer screening behaviors. Prev Med. 2016 Apr; 85:47-52.
    View in: PubMed
    Score: 0.042
  38. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol. 2016 Jan; 2(1):85-93.
    View in: PubMed
    Score: 0.042
  39. Use of surveillance imaging following treatment of small renal masses. J Urol. 2013 Nov; 190(5):1680-5.
    View in: PubMed
    Score: 0.035
  40. Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int. 2013 Aug; 112(4):E273-80.
    View in: PubMed
    Score: 0.035
  41. Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. J Urol. 2012 Sep; 188(3):775-80.
    View in: PubMed
    Score: 0.033
  42. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol. 2012 Jun; 61(6):1239-44.
    View in: PubMed
    Score: 0.032
  43. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011 Apr 20; 29(12):1517-24.
    View in: PubMed
    Score: 0.030
  44. Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer. 2011 Nov 01; 117(21):4846-54.
    View in: PubMed
    Score: 0.030
  45. Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. Urology. 2011 Feb; 77(2):402-6.
    View in: PubMed
    Score: 0.029
  46. Patterns of care for radical prostatectomy in the United States from 2003 to 2005. J Urol. 2008 Nov; 180(5):1969-74.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.